**CHARITY REGISTRATION NUMBER: 1205000 COMPANY REGISTRATION NUMBER: CE033752** 


## **Axial Spondyloarthritis International Federation Report and Accounts** 

## **31 December 2025** 

## **GORDON & CO** 

Chartered Accountants and Business Advisors 

4 Bloomsbury Square London WC1A 2RP 



## **Axial Spondyloarthritis International Federation** 

## **Contents** 

## **Year ended 31 December 2025** 

||**Page**|
|---|---|
|Reference and administrative details|**1**|
|Trustees' annual report|**2**|
|Independent examiner’s report to the Trustees|**7**|
|Statement of financial activities|**8**|
|Statement of financial position|**9**|
|Notes to the accounts|**10**|





**Axial Spondyloarthritis International Federation Reference and Administrative Details** 

## **Year ended 31 December 2025** 

**Reference and administrative details Registered charity name** Axial Spondyloarthritis International Federation **Charity registration number** 1205000 **Company registration number** CE033752 **Registered office** 27 Old Gloucester Street London WC1N 3AX **The Trustees** Zhivko Yankov - Chair René Bräm - Treasurer From 1 February 2025 Lillann Wermskog – Vice- Chair Andri Phoka Secretary to October 2025 Nadia Malliou Secretary from October 2025 Dr Tuncay Duruöz Cassie Shafer Prachee Bhosle Julieth Buitrago Geraldine M Bonites From October 2025 Simon Grosswiler From October 2025 **Staff and volunteers** Jo Davies Director of Operations Jo Lowe Project Manager Joanne de Bry Communications Manager **Advisor** Fiona Kerin FCA Accountant **Bankers** HSBC UK Bank PLC CAF Bank 15 Wellington Street 25 Kings Hill Avenue Woolwich Kings Hill London West Malling SE18 6PH Kent ME19 4JQ **Independent examiner** John Gordon FCA Gordon & Co 4 Bloomsbury Square London WC1A 2RP 

**1** 



## **Axial Spondyloarthritis International Federation Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation** 

## **Year ended 31 December 2025** 

The Trustees present their report and the accounts of the charity for the year ended 31 December 2025. 

Axial Spondyloarthritis International Federation ("ASIF") has been in existence as a charity since 1988. Following approval from the members at an AGM in 2022, the charity was registered as a Charitable Incorporated Organisation (CIO) on 2 October 2023. 

## **Structure, governance and management** 

## Constitution 

ASIF is a charitable incorporated organisation (CIO), formed in 1988, comprising a world network of societies and associations representing patients suffering from Axial Spondyloarthritis ("axSpA"). These societies and associations are members of ASIF. 

ASIF's constitution includes the requirement that a general meeting of all members of ASIF must be held annually, at which Trustees are elected to manage the affairs of the association. 

The CIO constitution allows that Trustees can be either a nominated representative of a member organisation or other persons who are elected on the basis of relevant skills and experience that they will bring to the charity trustee board. 

The constitution requires that there are a minimum of five Trustees and a maximum of twelve Trustees. Trustees are normally appointed for a term of three years and a maximum of three terms. 

## Management 

ASIF is overseen by the Trustees, who meet at least four times a year. Working with the staff team, the Trustees determine ASIF policies, decide on the strategic direction of ASIF and review existing funds and set budgets for future expenditure. Decisions are made by a simple majority vote. 

Trustees are entitled to claim reimbursement of expenses. 

The staff team are led by the Director of Operations who works closely with the Chair and the Trustees to determine the strategic direction of the charity and with the staff team to operational the strategic plan. 

## Risk assessment 

The Trustees have reviewed the risks faced by ASIF and have adopted appropriate policies to mitigate these risks. These risks are reviewed periodically by the Trustees. The Trustees believe that ASIF has sufficient resources for the time being to support its activities. 

## **Objectives and activities** 

ASIF's mission is _A world where everyone affected by axSpA lives their best life._ The Object of the Charity is: 

**2** 



## **Axial Spondyloarthritis International Federation Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation** 

## **Year ended 31 December 2025** 

_"The relief of sickness and preservation of health by advancing the diagnosis and treatment of persons suffering from, Axial Spondyloarthritis and its related conditions throughout the world through promoting awareness and funding and encouraging research into, the causes, diagnosis and effective treatments of Axial Spondyloarthritis and its related conditions throughout the world and disseminating the results of such research worldwide."_ 

ASIF seeks to achieve this objective through organising conferences for member organisations, running global projects and disseminating information to members, public and stakeholders, and through making presentations to and working with affiliated groups including representatives of the pharmaceutical industry. 

## **Achievements and performance** 

In 2025 ASIF continued to develop its major projects: 

## World AS Day 

WAS Day remains ASIF’s main annual global awareness campaign. In 2025 WAS Day was on 3 May, however the campaign runs throughout April and May.  The social media campaign reached an incredible 23.7 million people worldwide and the video play were up 264% on the previous year at 6.2 million. The campaign tools were made available, ready to use, to our members, with the ability for them easily to translate the language and add their own organisational branding. 

The 2025 theme was ‘Lace Up For axSpA’ which highlighted everyday challenges faced by people living with axSpA. We awarded seven social media grants to members to boost their campaigns and send traffic to their own website pages. 

Many members and industry partners held events including webinars. The Spondylitis Association of America ran the annual Global Spondyloarthritis Summit which provides insightful presentations for people affected by axSpA.  Walk Your AS Off, a global virtual awareness and fundraising walk continues to create some keen competition around the world. 

## LAMAS 

Following on from the success of IMAS, the International Map of Axial Spondyloarthritis coupled with the success of the Latin American regional meeting held in Bogotá in October 2024, it was decided that ASIF would produce a regional report focussed on the IMAS data collected in Latin America called the Latin American Map of Axial Spondyloarthritis. A working group was created with patients and HCPs from the region and statistical analysis provided by Marco Garrido Cumbrera of the University of Seville.  This work continued throughout 2025, the report will be launched at PANLAR in April 2026. 

## IMAS/IMAP 

The International Map of Axial Spondyloarthritis (IMAS) was a comprehensive online patient survey of individuals living with axSpA; it assessed the impact and burden of the disease from the patient perspective and on healthcare utilisation.  In 2024, Novartis, who funded IMAS, transferred the assets to ASIF.  During 2025, trustees and staff considered what, if anything, should be done with 

**3** 



## **Axial Spondyloarthritis International Federation Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation** 

## **Year ended 31 December 2025** 

IMAS.  Members, trustees and scientific advisors were consulted and allagreed that the survey should be run again.  Now fully owned by ASIF, the upcoming study will address new relevant aspects of both axial spondyloarthritis and psoriatic arthritis (PsA), incorporate perspectives from a broader range of countries, and provide new essential data for patient organisations, researchers, clinicians and other stakeholders.  Towards the end of 2025, a concept note for the new project the International Map of axSpA and PsA (IMAP), was drafted and research funding sought. ASIF was successful in securing the first funder for this study, Alfasigma, at the end of 2025. The project will launch early in 2026, focussing initially on Europe, whilst further funding is sought to take IMAP to the rest of the world. 

## Expert Advisory Committee 

In March 2025 the first meeting of the newly formed Expert Advisory Committee was held. Members of that committee are listed on the ASIF website.  Members include representatives from rheumatology, physiotherapy, psychology, nursing, academic research, epidemiology and patient representatives.  Their remit is to advise on the framing, design and delivery of ASIF’s work from the perspective of healthcare professionals, to serve as a forum to discuss potential areas of collaboration between patient organisations and professional healthcare sectors and to support ASIF in building partnerships. 

## Research Projects 

ASIF is growing its reputation and capacity to be involved in global research projects, by industry partners and by ASAS (an international group of experts in the field of spondyloarthritis). 

ASIF supported a survey on the ASAS Quality Standards, which was led by an independent research agency on behalf of AbbVie.  ASIF’s Project Manager worked with the agency to co-create patient advertising materials and worked with patient organisations in 24 countries to disseminate the survey. 

ASAS projects that ASIF took part in, include: PRAXIS for which ASIF recruited patients to complete a patient version of a survey for a study that seeks to formulate recommendations for the assessment of axSpA in daily clinical practice.  ASIF provided PRPs for the working group that in 2025 published a new international definition of difficult-to-manage (D2M) axSpA.  The aim was to create a shared definition so that patients, clinicians, researchers and advocacy groups can better identify unmet needs and improve care. 

## Global Remission Coalition 

ASIF was delighted to be one of the founding members of the Global Remission Coalition that was launched on 21 May 2025 on the side of the World Health Assembly in Geneva, Switzerland.  The main aim of the coalition will be to raise awareness about the value of remission and advocate for policies that prioritise the pursuit of remission. 

**4** 



## **Axial Spondyloarthritis International Federation Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation** 

## **Year ended 31 December 2025** 

## **Plans for 2026** 

ASIF’s main areas of focus in 2026 will be: 

## ASIF Council Meeting 

One of the key events for ASIF members, the Council Meeting in 2026 will be held in Athens in October.  A main objective of the Council Meeting is to inspire members to grow the work they are doing and to strengthen their organisations.  The theme of this Council Meeting is ‘Collaboration’. 

## World AS Day 

World AS Day will take place on 2 May 2026, with the theme ‘Not only back pain’.  Highlighting the comorbidities and Extra Musculoskeletal Manifestations that people living with axSpA experience. The campaign will raise awareness throughout April and May. 

## IMAP/EMAP 

Work will continue to develop the study protocol, survey design and governance for the study. The study will be launched in Europe and fundraising will continue to secure finance for the global element of the study. 

## **Financial review** 

## Overview 

During the year ASIF’s total income was £257,243 (2024 - £329,517) of which £214,418 (2024 - £314,350) was grant income. Grant income includes £109,140 (2024 - £92,701) restricted to specific activities. 

ASIF’s total expenditure was £274,686 (2024 - £419,477) including £270,786 (2024 - £415,517) spent on charitable activities. 

ASIF’s income reduced in 2025 compared to previous years, largely due to the sudden loss of a major supporter.  Some of that loss was offset by the contract work that was carried out in support of research.  Staff have worked hard to forge new funding relationships and also by diversifying the work to include ASIF carrying out a major research study of its own, forecast income for 2026 is looking healthier. 

## Investment performance 

ASIF's funds are held with HSBC and at CAF Bank. In 2025 Trustees approved the opening of a currency transfer account, Currencies Direct.  That has now been opened and will create savings on international transactions.  Trustees have approved that plans be made to close the HSBC accounts and transfer all holdings to CAF Bank. 

## Fundraising 

ASIF does not seek to raise funds direct from the public; instead it solicits support from the 

**5** 



## **Axial Spondyloarthritis International Federation Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation** 

## **Year ended 31 December 2025** 

pharmaceutical industry and from associated institutions and charitable organisations. 

## Reserves 

At the end of 2025 restricted funds carried forward totalled £87,201 (2024 - £17,050) and unrestricted funds carried forward totalled £125,350 (2024 - £212,944) which represents grant and sponsorship income from pharmaceutical partners for on-going projects. 

Reserves are calculated on unrestricted funds, and at the year end were at 7 months which whilst at the lower end, is within the reserves policy. 

The restricted funds are those amounts set aside to fund specific projects for which grants from pharmaceutical companies and other interested institutions are solicited. The unrestricted funds represent accumulated surplus income and unrestricted sponsorship funding and can be expended in accordance with ASIF's objectives without further restriction. 

## **Statement of Trustees’ responsibilities** 

The Trustees are responsible for preparing a Trustees’ Annual Report and accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Trustees are required to prepare accounts for each financial year which give a true and fair view of the state of affairs of ASIF and of the incoming resources and application of funds for that year. In preparing those accounts, the Trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the applicable accounting standards; 

- make judgements and accounting estimates that are reasonable and prudent; 

- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the accounts; and 

- prepare the accounts on a going concern basis unless it is inappropriate to presume that ASIF will continue in operation. 

The Trustees are responsible for keeping proper accounting records that are sufficient to show and explain the transactions undertaken and to disclose with reasonable accuracy at any time the financial position of ASIF and to enable them to ensure that the accounts comply with relevant regulations and the provisions of the Constitution. They are also responsible for safeguarding the assets of ASIF and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

The Trustees are responsible for the maintenance and integrity of the financial information included on ASIF’s website. Legislation in the United Kingdom governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions. 

## **Independent examiner** 

**6** 



## **Axial Spondyloarthritis International Federation Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation** 

## **Year ended 31 December 2025** 

John Gordon FCA is the charity's independent examiner. 

The Trustees' Annual Report was approved on 18 May 2026 and signed on behalf of the board of Trustees by: 

Nadia Malliou Secretary 

I report to the Trustees on my examination of the accounts of Axial Spondyloarthritis International Federation ('the charity') for the year ended 31 December 2025. 

## **Responsibilities and basis of report** 

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (‘the Act’). 

I report in respect of my examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act. 

## **Independent examiner's statement** 

Since the charity’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales (ICAEW), which is one of the listed bodies. 

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 

**7** 



## **Axial Spondyloarthritis International Federation Independent Examiner's Report to the Trustees of Axial Spondyloarthritis International Federation** 

## **Year ended 31 December 2025** 

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or 

2. the accounts do not accord with those records; or 

3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a ‘true and fair' view which is not a matter considered as part of an independent examination. 

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. 

John Gordon FCA Independent Examiner 

4 Bloomsbury Square London WC1A 2RP 

18 May 2026 

**8** 



## **Axial Spondyloarthritis International Federation** 

## **Statement of Financial Activities** 

## **Year ended 31 December 2025** 

||||**2025**||2024|
|---|---|---|---|---|---|
|||Unrestricted|Restricted|||
|||funds|funds|**Total funds**|Total funds|
||**Note**|<br>**£**|**£**|**£**|£|
|**Incoming resources**||||||
|Donations and subscriptions|**5**|<br>-|-|-|5,018|
|Grants received|**6**|<br>105,278|109,140|214,418|314,350|
|Other|**7**|<br>40,632|-|40,632|-|
|Investment income|**8**|<br>2,193|-|2,193|10,149|
|||--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|**Total incoming resources**||148,103|109,140|257,243|329,517|
|||================================|================================|================================|================================|
|**Expenditure**||||||
|Expenditure on charitable activities||231,797|38,989|270,786|415,517|
|Governance costs|**9**|<br>3,900|-|3,900|3,960|
|||--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|**Total resources expended**||235,697|38,989|274,686|419,477|
|||================================|================================|================================|================================|
|||--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|**Net movement in funds**|**10**|87,594|70,151|(17,443)|(89,960)|
|||================================|================================|================================|================================|
|Total funds brought forward||212,944|17,050|229,994|319,954|
|||--------------------------------|--------------------------------|--------------------------------|-------------------------------|
|**Total funds carried forward**|**16**|125,350|87,201|212,551|229,994|
|||================================|================================|================================|================================|



The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. 

**The notes on pages 11 to 18 form part of these accounts.** 

**9** 



## **Axial Spondyloarthritis International Federation** 

## **Statement of Financial Position** 

## **31 December 2025** 

|||**2025**|2024|
|---|---|---|---|
||**Note**|**£**|£|
|**Current assets**||||
|Debtors|**14**|123,979|17,050|
|Cash at bank and in hand||98,759|223,442|
|||--------------------------------|--------------------------------|
|||222,738|240,492|
|||--------------------------------|--------------------------------|
|**Creditors: amounts falling due within one year**|**15**|10,187|10,498|
|||--------------------------------|--------------------------------|
|**Total assets less current liabilities**||212,551|229,994|
|**Net assets**||212,551|229,994|
|||================================|================================|
|**Funds of the charity**||||
|Restricted funds||87,201|17,050|
|Unrestricted funds||125,350|212,944|
|||--------------------------------|--------------------------------|
|**Total charity funds**|**16**|212,551|229,994|
|||================================|================================|



These accounts were approved by the board of Trustees and authorised for issue on 18 May 2026, and are signed on behalf of the board by: 

Zhivko Yankov Chairman 

Nadia Malliou Secretary 

**The notes on pages 11 to 18 form part of these accounts.** 

**10** 



## **Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## **1. General information** 

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the registered office is 27 Old Gloucester Street, London, WC1N 3AX. 

## **2. Statement of compliance** 

These accounts have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011. 

## **3. Accounting policies** 

## **Basis of preparation** 

The accounts have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure. 

The accounts are prepared in Sterling, which is the functional currency of the charity. Monetary amounts in these accounts are rounded to the nearest £1. 

## **Going concern** 

There are no material uncertainties about the charity's ability to continue. 

## **Judgements and key sources of estimation uncertainty** 

The preparation of the accounts requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. 

## **Foreign currencies** 

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the statement of financial activities. 

**11** 



## **Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## **Fund accounting** 

Restricted funds are maintained where the funds raised are to be used for specific purposes. Accumulated surplus income, which forms the Fund’s reserves, is retained in unrestricted funds. Reserves are maintained to meet the Fund’s continuing obligations and to cater for future needs and contingencies. Unrestricted funds comprise those funds which the Trustees are free to use for any purposes in furtherance of the charitable objects. 

## **Incoming resources** 

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income: 

- grants received from pharmaceutical companies towards shared costs are included in the Statement of Financial Activities when received or deferred to the extent that they relate to future accounting periods; 

- income from donations is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably; and 

- donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers. 

## **Resources expended** 

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates: 

- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities; and 

- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities. 

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis. 

**12** 



**Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## **Financial instruments** 

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. 

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. 

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted. 

Debt instruments are subsequently measured at amortised cost. 

## **4. Transfer of funds** 

On 1 January 2024 the unrestricted and restricted funds in the charity Axial Spondyloarthritis International Federation (charity number 1173902) were transferred to Axial Spondyloarthritis International Federation (charity number 1205000). 

## **5. Donations and subscriptions** 

||Unrestricted|**Total Funds**|Unrestricted|Total Funds|
|---|---|---|---|---|
||Funds|**2025**|Funds|2024|
||£|**£**|£|£|
|**Donations**|||||
|Donations|-|-|1,219|1,219|
|Council meeting fees|-|-|3,799|3,799|
||----------------------------------|----------------------------------|---------------------------|----------------------------|
||-|-|5,018|5,018|
||============================|=============================|=======================|=======================|



The charity no longer charges a subscription fee for membership. 

## **6. Grants received** 

||Unrestricted|Restricted|**Total Funds**|
|---|---|---|---|
||Funds|Funds|**2025**|
||£|£|**£**|
|Pharma grants - unrestricted|105,278|-|105,278|
|Pharma grants - restricted|-|109,140|109,140|
||-------------------------------------|--------------------------------------|---------------------------------------|
||105,278|109,140|214,418|
||=================================|================================|=================================|



**13** 



**Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## **6. Grants received (continued)** 

|||Unrestricted|Restricted|Total Funds|
|---|---|---|---|---|
|||Funds|Funds|2024|
|||£|£|£|
|Pharma grants - unrestricted||221,649|-|221,649|
|Pharma grants - restricted||-|92,701|92,701|
|||----------------------------------------|--------------------------------------|---------------------------------------|
|||221,649|92,701|314,350|
|||=================================|================================|=================================|
|**Other income**|||||
||Unrestricted|**Total Funds**|Unrestricted|Total Funds|
||Funds|**2025**|Funds|2024|
||£|**£**|£|£|
|Contract work|40,632|40,632|-|-|
||=============================|=============================|=======================|=======================|
|**Investment income**|||||
||Unrestricted|**Total Funds**|Unrestricted|Total Funds|
||Funds|**2025**|Funds|2024|
||£|**£**|£|£|
|Bank interest receivable|2,193|2,193|10,149|10,149|
||==============|==============|=======================|=======================|
|**Governance costs**|||||
||Unrestricted|**Total Funds**|Unrestricted|Total Funds|
||Funds|**2025**|Funds|2024|
||£|**£**|£|£|
|Accountancy fees|2,400|2,400|2,400|2,400|
|Independent examination fees|1,500|1,500|1,560|1,560|
||----------------------------------|----------------------------------|-----------------------------|------------------------------|
||3,900|3,900|3,960|3,960|
||============================|=============================|=======================|=======================|
|**Net income**|||||
|Net income is stated after charging:|||||
||||**2025**|2024|
||||**£**|£|
|Foreign exchange differences|||551|5,730|
||||=========================|=======================|



## **7. Other income** 

## **8. Investment income** 

## **9. Governance costs** 

## **10. Net income** 

Net income is stated after charging: 

**14** 



## **Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## **11. Independent examination fees** 

||**2025**|2024|
|---|---|---|
||**£**|£|
|Fees payable to the independent examiner for:|||
|Independent examination of the accounts|1,500|1,560|
||=======================|==============|



## **12. Staff costs** 

The average monthly number of employees (excluding trustees) during the year was: 

||||**2025**|2024|
|---|---|---|---|---|
|Administration and organisation|||3|4|
||||=======================|==============|
||Unrestricted|**Total Funds**|Unrestricted|Total Funds|
||Funds|**2025**|Funds|2024|
||£|**£**|£|£|
|Wages and salaries|147,666|147,666|224,582|224,582|
|Social security costs|2,410|2,410|13,235|13,235|
|Other pension costs|6,446|6,446|10,145|10,145|
||----------------------------------|----------------------------------|----------------------------------|----------------------------------|
||156,522|156,522|247,961|247,961|
||============================|=============================|============================|=============================|



One employee earned between £60,000 and £70,000 per annum in respect of the year ended 31 December 2025 (2024 – one employee between £100,000 and £109,999). 

## **13. Trustee remuneration and expenses** 

During the year ended 31 December 2025, six Trustees were reimbursed a total of £13,538 (2024 - £13,923) for expenses incurred including travel, accommodation and subsistence, in relation to the charity’s activities. 

## **14. Debtors** 

||**2025**|2024|
|---|---|---|
||**£**|£|
|Other debtors|123,979|17,050|
||--------------------------------------|-----------------------------------|
||123,979|17,050|
||=================================|=============================|



**15** 



## **Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## **15. Creditors: amounts falling due within one year** 

||**2025**|2024|
|---|---|---|
||**£**|£|
|Social security and other taxes|5,783|1,766|
|Accruals and deferred income|4,404|8,732|
||--------------------------------------|-----------------------------------|
||10,187|10,498|
||=================================|=============================|



## **16. Analysis of charitable funds** 

## **Unrestricted funds** 

||||||Transfer (to)||
|---|---|---|---|---|---|---|
|||At|||/ from|**At 31**|
||1|January|||restricted|**December**|
|||2025|Income|Expenditure|funds|**2025**|
|||£|£|£|£|£|
|General funds||212,944|148,103|(235,697)|<br>-|125,350|
|||===================================|========================================|================================|=====================================|===================================|
||||||Transfer (to)||
|||At|||/ from|At 31|
||1|January|||restricted|December|
|||2024|Income|Expenditure|funds|2024|
|||£|£|£|£|£|
|General funds||283,932|236,816|(143,599)|<br>(164,205)|<br>212,944|
|||===================================|=====================================|=================================|===============================|================================|



Unrestricted funds of £283,932 were transferred to charity 1205000 on 1 January 2024. Refer to note 4. 

## **Restricted funds** 

|||||||Transfer (to)||
|---|---|---|---|---|---|---|---|
||||At|||/ from|**At 31**|
||||1 January|||unrestricted|**December**|
||||2025|Income|Expenditure|funds|**2025**|
||||£|£|£|£|£|
|World AS Day (WAS Day)|||-|12,829|(12,829)|<br>-|-|
|International Map||of Axial||||||
|Spondyloarthritis|(IMAS)||-|-|-|-|-|
|Delay to Diagnosis (D2D)|||-|-|-|-|-|
|International Map||of Axial||||||
|Spondyloarthritis||and||||||
|Psoriatic Arthritis|(IMAP)||-|87,758|(557)|<br>-|87,201|
|Other|||17,050|8,553|(25,603)|<br>-|-|
||||-----------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------------------|-----------------------------------------|
||||17,050|109,140|(38,989)|<br>-|87,201|
||||================================|================================|================================|====================================|===================================|



**16** 



**Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## **16. Analysis of charitable funds (continued)** 

|||||||Transfer (to)||
|---|---|---|---|---|---|---|---|
||||At|||/ from|At 31|
||||1 January|||unrestricted|December|
||||2024|Income|Expenditure|funds|2024|
||||£|£|£|£|£|
|World AS Day (WAS Day)|||-|-|(53,781)|<br>53,781|-|
|International Map||of Axial||||||
|Spondyloarthritis|(IMAS)||36,022|29,954|(94,249)|<br>28,773|-|
|Delay to Diagnosis (D2D)|||-|12,913|(28,798)|<br>15,885|-|
|International Map||of Axial||||||
|Spondyloarthritis||and||||||
|Psoriatic Arthritis|(IMAP)||-|-|-|-|-|
|Other|||-|49,834|(99,050)|<br>66,266|17,050|
||||-----------------------------------------|-----------------------------------------|---------------------------------------------|---------------------------------|-----------------------------------------|
||||36,022|92,701|(275,878)|<br>164,205|17,050|
||||===================================|=================================|====================================|==========================|================================|



Restricted funds of £36,022 were transferred to charity 1205000 on 1 January 2024. Refer to note 4. 

International Map of Axial Spondyloarthritis (IMAS) and the International Map of Axial Spondyloarthritis and Psoriatic Arthritis (IMAP) 

IMAS was a project managed by ASIF in partnership with Novartis and the University of Seville. IMAS.  It wasa global survey which generates and disseminates evidence about how people with axSpA experience their disease physically, psychologically and socially. 

As of 2 January 2024, the International Map of axSpA is owned solely by the Axial Spondyloarthritis International Federation following an in-kind donation of the project by Novartis Pharma AG. 

The value of the assets received by ASIF cannot be reliably measured and therefore no value is assigned to them in these accounts. 

In consultation with members, trustees and other stakeholders including representatives of the global axSpA research community, it was agreed that a new project. IMAP should be launched, which would learn from the limitations of the first project IMAS.  IMAP will start to collect data in 2027. 

## Delay to Diagnosis (D2D) 

The objectives of this project are to significantly reduce the average time to diagnosis internationally; and to globally raise awareness about the disease and the detrimental effects of the delay, physically, psychologically and economically. In 2021 we produced a Global Burden Statement and built awareness and advocacy tools for our members. 

**17** 



**Axial Spondyloarthritis International Federation** 

## **Notes to the Accounts** 

## **Year ended 31 December 2025** 

## Other 

This includes Development of a psychosocial network for members and World AS Day. 

## **17. Analysis of net assets between funds** 

||Unrestricted|Restricted|**Total Funds**|
|---|---|---|---|
||Funds|Funds|**2025**|
||£|£|**£**|
|Current assets|135,537|87,201|222,738|
|Creditors less than 1 year|(10,187)|-|(10,187)|
||-----------------------------------------|------------------------------------|--------------------------------|
|**Net assets**|125,350|87,201|212,551|
||=================================|===============================|================================|
||Unrestricted|Restricted|Total Funds|
||Funds|Funds|2024|
||£|£|£|
|Current assets|223,442|17,050|240,492|
|Creditors less than 1 year|(10,498)|–|(10,498)|
||----------------------------------------|-------------------------------------|-----------------------------------------|
|**Net assets**|212,944|17,050|229,994|
||==================================|================================|==================================|



**18** 

